戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ng topical agents, surgery, or definitive or adjuvant radiation therapy.
2 % in stages II and III has led to the use of adjuvant radiation therapy.
3 erall mortality, colostomy rates, and use of adjuvant radiation therapy.
4 m mortality, permanent colostomy, and use of adjuvant radiation therapy.
5 -one patients (25%) were selected to receive adjuvant radiation therapy.
6 temic adjuvant therapy and 35% also received adjuvant radiation therapy.
7 oral cavity cancer who underwent surgery and adjuvant radiation therapy.
8 ten necessitate concurrent chemotherapy with adjuvant radiation therapy.
9 as used as the basis for recommendations for adjuvant radiation therapy.
10 llowed by surgical resection with or without adjuvant radiation therapy.
11 r for subtotally resected EPN_PFA, even with adjuvant radiation therapy.
12 ients; chemotherapy, 41 (43%); definitive or adjuvant radiation therapy, 34 (RT; 35%); and targeted t
13  was associated with decreased likelihood of adjuvant radiation therapy after breast conservation.
14 lumpectomy, receipt of chest reconstruction, adjuvant radiation therapy after lumpectomy, neoadjuvant
15                                 She received adjuvant radiation therapy and initiated letrozole, with
16 ed treatment-naive cohorts (both primary and adjuvant radiation therapy) and those with recurrent dis
17 treatment group: lumpectomy, lumpectomy with adjuvant radiation therapy, and mastectomy.
18                                              Adjuvant radiation therapy appears detrimental to surviv
19                                              Adjuvant radiation therapy appears detrimental to surviv
20                                              Adjuvant radiation therapy (ART) for stage I seminoma ca
21 e patients treated with BCT (lumpectomy with adjuvant radiation therapy) at the Medical College of Vi
22                                              Adjuvant radiation therapy became the standard of care a
23 ion-sparing resection is appropriate because adjuvant radiation therapy can offset the adverse impact
24 over 1400 patients have examined the role of adjuvant radiation therapy compared with observation fol
25                The increasing utilization of adjuvant radiation therapy, especially for early-stage b
26 pear to have systematic access problems with adjuvant radiation therapy following BCS compared with w
27         Prior studies have demonstrated that adjuvant radiation therapy following mastectomy for brea
28 randomized trials, indications for immediate adjuvant radiation therapy following prostatectomy exist
29                                   The use of adjuvant radiation therapy following prostatectomy is co
30  recommended to assess benefits and risks of adjuvant radiation therapy for each patient with N2 dise
31 f using a genomic risk model for deciding on adjuvant radiation therapy for prostate cancer treated w
32 G, AND PARTICIPANTS: The Stereotactic Pelvic Adjuvant Radiation Therapy in Cancers of the Uterus (SPA
33 e of randomized studies, the real benefit of adjuvant radiation therapy in MCC is unclear.
34                                              Adjuvant radiation therapy in the management of early st
35  this study was to better define the role of adjuvant radiation therapy in the management of MCC.
36                    Prospective evaluation of adjuvant radiation therapy in this setting is warranted.
37                         Surveillance without adjuvant radiation therapy is a reasonable option for wo
38  can provide low local recurrence rates when adjuvant radiation therapy is administered.
39                                   The use of adjuvant radiation therapy is associated with improved s
40                                              Adjuvant radiation therapy is not recommended for patien
41      In patients with stage IIIA N2 disease, adjuvant radiation therapy is not recommended for routin
42 ify patients who may have a greater need for adjuvant radiation therapy machine learning technology.
43       All subjects received standard-of-care adjuvant radiation therapy or chemotherapy before study
44 for nodal disease, estrogen receptor status, adjuvant radiation therapy or chemotherapy, neither DFS
45                  After surgery (with/without adjuvant radiation therapy), patients received adjuvant
46                           The routine use of adjuvant radiation therapy remains a controversial topic
47                     To determine the optimal adjuvant radiation therapy (RT) dose following resection
48                                              Adjuvant radiation therapy (RT) has been shown to improv
49                                              Adjuvant radiation therapy (RT) has consistently demonst
50                               The benefit of adjuvant radiation therapy (RT) in stage I endometrial a
51 , respectively, as well as use of salvage or adjuvant radiation therapy (RT) or androgen deprivation
52 kemia Group B (CALGB) C9343 trial found that adjuvant radiation therapy (RT) provided minimal benefit
53                                   The use of adjuvant radiation therapy (RT) to the primary site in M
54 egative margin width and LRR with or without adjuvant radiation therapy (RT).
55 eated with breast-conserving surgery without adjuvant radiation therapy (RT).
56                                              Adjuvant radiation therapy should be considered in men w
57 omplished by complete surgical resection +/- adjuvant radiation therapy should impact strongly on DSS
58                                              Adjuvant radiation therapy use decreased over time indep
59 median survival for those patients receiving adjuvant radiation therapy was 63 months compared with 4
60                                              Adjuvant radiation therapy was obviated in 5 of 17 patie
61 gher for low-volume surgeons, and the use of adjuvant radiation therapy was significantly lower for l
62      Use of LE versus proctectomy and use of adjuvant radiation therapy were compared over time.